Search Results - "O'Shaughnessy, Aisling"

Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia‐reperfusion injury by Farrar, Conrad A., Keogh, Brian, McCormack, William, O'Shaughnessy, Aisling, Parker, Andrew, Reilly, Mary, Sacks, Steven H.

“…ABSTRACT Toll‐like receptors (TLRs) are important molecules involved in the activation of innate and subsequent development of adaptive immunity. TLRs are…”
Get full text

Histone H2A phosphorylation and H3 methylation are required for a novel Rad9 DSB repair function following checkpoint activation by Toh, Geraldine W.-L., O'Shaughnessy, Aisling M., Jimeno, Sonia, Dobbie, Ian M., Grenon, Muriel, Maffini, Stefano, O’Rorke, Anne, Lowndes, Noel F.

“…In budding yeast, the Rad9 protein is an important player in the maintenance of genomic integrity and has a well-characterised role in DNA damage checkpoint…”
Get full text

Docking onto chromatin via the Saccharomyces cerevisiae Rad9 Tudor domain by Grenon, Muriel, Costelloe, Thomas, Jimeno, Sonia, O'Shaughnessy, Aisling, FitzGerald, Jennifer, Zgheib, Omar, Degerth, Linda, Lowndes, Noel F.

“…An integrated cellular response to DNA damage is essential for the maintenance of genome integrity. Recently, post‐translational modifications to histone…”
Get full text

Multiple approaches to study S. cerevisiae Rad9, a prototypical checkpoint protein by O'Shaughnessy, Aisling M, Grenon, Muriel, Gilbert, Chris, Toh, Geraldine W-L, Green, Catherine M, Lowndes, Noel F

“…The Saccharomyces cerevisiae RAD9 checkpoint gene is the prototypical checkpoint gene and is required for efficient checkpoint regulation in late G1, S, and at…”
Get more information

Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer by Knights, Charlotte, Chresta, Christine, Riches, Lucy, Mangena, Ramu, Avis, Tim, O'Shaughnessy, Aisling, Unwin, Louise, Dunham, Victoria, Jones, Louise, Cranston, Aaron, Carmichael, Jim, Martin, Niall, O'Connor, Mark, Lau, Alan

“…Background: The oral PARP inhibitor olaparib (AZD2281, KU-0059436) has shown anti-tumor activity in patients with hereditary BRCA mutations and provides…”
Get full text

Abstract 3497: Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib by Dry, Jonathan R., Lau, Alan, Knights, Charlotte, Harbron, Chris, Prime, John E., Riches, Lucy, Mangena, Rama, Avis, Tim, Brown, Helen, Runswick, Sarah, Dearden, Simon, O'Shaughnessy, Aisling, Unwin, L, French, Tim, Hodgson, Darren, O'Connor, Mark J.

“…Background: Early results from Phase II trials have shown that treatment with the PARP inhibitor olaparib (AZD2281, KU-0059436) can induce tumour specific…”
Get full text

Abstract C119: Identification of gene expression biomarkers that predict sensitivity to the PARP inhibitor olaparib by Lau, Alan, Dry, Jonathan, Harbron, Chris, Knights, Charlotte, Riches, Lucy, Mangena, Ramu, Avis, Tim, Brown, Helen, Runswick, Sarah, Dearden, Simon, O'Shaughnessy, Aisling, Unwin, Louise, Prime, John E., Hodgson, Darren, Carmichael, James, O'Connor, Mark J.

“…Background: The oral PARP inhibitor olaparib (AZD2281, KU-0059436) is in Phase II clinical trials in patients with BRCA-mutated breast and ovarian cancer…”
Get full text